Other substances

Bendamustine

An alkylating agent.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Bendamustine is an alkylating agent. It might alkylate and crosslink macromolecules, which leads to the induction of apoptosis (NCIt).

Bendamustine on DrugBank
Bendamustine on PubChem
Bendamustine on Wikipedia

Marketed as

LEVACT; TREAKISYM; TREANDA (BENDAMUSTINE HYDROCHLORIDE); BENDEKA (BENDAMUSTINE HYDROCHLORIDE); BENDAMUSTINE HYDROCHLORIDE; BELRAPZO (BENDAMUSTINE HYDROCHLORIDE)

CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2 Small molecule Enzyme assay Screening	in vitro	6.71	Inhibits SARS-CoV-2 3C-like protease in vitro.	Jul/28/2020

AI-suggested references

Link	Publication date
Rescue Therapy of Refractory Diffuse Large B-Cell Lymphomas BCL2 with Venetoclax: Case Report.	May/21/2020
Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma.	Jun/08/2021
Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: A case report	May/04/2022
The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study.	Apr/28/2021
A Fatal Breakthrough Coronavirus Disease 2019 Case Following Bendamustine-Rituximab Therapy	Apr/30/2022

Export (.csv)